GlassScriptPhysician profile
Kadia Tracey
NPI 1326847971
$3,139.12
in general payments reported to CMS, 2019-2025
28 companies · $3,139 in 2025
The $3,139 reported for 2025 was more than what 97% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345 · Long Term Medical Supply Or Device Loan: $399 · Education: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.35 |
| Long Term Medical Supply Or Device Loan | $398.80 |
| Education | $394.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $468.48 | 2025 | Carvykti, Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $429.89 | 2025 | |
| Sobi, INC | $410.63 | 2025 | |
| Astellas Pharma US INC | $293.34 | 2025 | Vyloy, Xospata, Xtandi |
| Beone Medicines USA, INC. | $171.54 | 2025 | Tevimbra, Brukinsa |
| Pfizer INC. | $147.87 | 2025 | |
| Geron Corporation | $145.54 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $124.46 | 2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $123.49 | 2025 | Enhertu |
| Exelixis INC. | $120.52 | 2025 | Cabometyx |
| Genentech USA, INC. | $115.94 | 2025 | Itovebi, Tecentriq, Polivy |
| Incyte Corporation | $76.03 | 2025 | Zynyz, Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $73.96 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Tersera Therapeutics LLC | $73.46 | 2025 | Zoladex, Xermelo |
| Glaxosmithkline, LLC. | $49.07 | 2025 | Ojjaara |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $45.80 | 2025 | |
| Array Biopharma INC | $41.51 | 2025 | Braftovi, Mektovi, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $24.96 | 2025 | Fruzaqla |
| Servier Pharmaceuticals LLC | $24.76 | 2025 | |
| Genmab U.S., INC. | $24.65 | 2025 | Epkinly |
| Iovance Biotherapeutics, INC. | $24.63 | 2025 | Amtagvi |
| Pharmacosmos Therapeutics INC. | $23.52 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $21.75 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.58 | 2025 | Libtayo |
| Genzyme Corporation | $17.40 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.52 | 2025 | Ultomiris |
| Agios Pharmaceuticals, INC. | $16.23 | 2025 | Pyrukynd |
| Taiho Oncology, INC. | $13.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kadia Tracey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.